MedPath

A study of pain reducing property of Terminalia chebula in healthy humans using pain model.

Not Applicable
Completed
Registration Number
CTRI/2014/01/004346
Lead Sponsor
izams Institute of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
24
Inclusion Criteria

• Healthy male participants aged 18 â?? 45yr, with a body mass index (BMI) 19.5 â?? 25.9 kg/m2 will be included in the study.

- Willing to give written informed consent to participate in the study.

• No history of Diabetes, Hypertension, recent use of analgesics

• Able to perform the test, as per the protocol procedure

Exclusion Criteria

• Uncooperative subjects.

• Prior wounds or fractures on the tested extremity

• Any significant abnormality identified on physical examination or laboratory tests.

• Smokers, Alcoholics, drug abusers (amphetamines, cocaine, sympathomimetics, systemic glucocorticoids, anabolic steroids) will be not included in the study.

• Participants using other anti oxidants and over the counter medications.

• Participants using other NSAIDS in the past 2 weeks.

• Use of other investigational drugs at the time of enrollment, or within 3 months prior to this study.

• History of hypersensitivity to any of the study drugs.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcome: Increase in the pain threshold and pain tolerance time compared to that of baseline. <br/ ><br> <br/ ><br>Timepoint: A total of 4 Time points <br/ ><br>1. Pre-drug <br/ ><br>2. One hour post-drug <br/ ><br>3. Two hour post-drug <br/ ><br>4. Three hour post-drug
Secondary Outcome Measures
NameTimeMethod
Safety & Tolerability of Terminalia chebula in healthy human participants.Timepoint: A total of 4 Time points <br/ ><br>1. Pre-drug <br/ ><br>2. One hour post-drug <br/ ><br>3. Two hour post-drug <br/ ><br>4. Three hour post-drug
© Copyright 2025. All Rights Reserved by MedPath